Contineum Therapeutics (CTNM) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Contineum Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 3 sold $1.9M of CTNM stock on the open market.
Get emailed when insiders cluster-buy stocks like CTNM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
CTNM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $270K | 7 |
| Q2 2026 | — | 0 | $962K | 7 |
| Q1 2026 | — | 0 | $532K | 15 |
| Q4 2025 | — | 0 | $95K | 2 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Contineum Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 3 insiders reported sales totaling $1.9M. 31 of 31 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 8SEC | Carmine N. StengoneCEO, President | Sell Plan | 2,50017,217 held (−13%) | $16.46 | $41K | -18.7% | — |
| Aug 3SEC | Carmine N. StengoneCEO, President | Sell Plan | 2,50017,217 held (−13%) | $16.01 | $40K | -16.4% | — |
| Jul 10SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 1,015135,202 held (−1%) | $16.00 | $16K | -16.4% | — |
| Jul 10SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 25135,202 held (−0%) | $16.00 | $400 | -16.4% | — |
| Jul 8SEC | Carmine N. StengoneCEO, President | Sell Plan | 2,50017,217 held (−13%) | $16.00 | $40K | -16.4% | — |
| Jul 2SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 28,826139,372 held (−17%) | $16.04 | $462K | -16.6% | — |
| Jul 2SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 5,852137,703 held (−4%) | $15.67 | $92K | -14.6% | — |
| Jul 2SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 2,501135,202 held (−2%) | $16.24 | $41K | -17.6% | — |
| Jul 1SEC | Tim WatkinsCmo & Head Of Development | Sell Plan | 10,8338,961 held (−55%) | $16.02 | $174K | -16.5% | — |
| Jul 1SEC | Carmine N. StengoneCEO, President | Sell Plan | 10,00017,217 held (−37%) | $16.01 | $160K | -16.4% | — |
| Jun 1SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 4,170139,372 held (−3%) | $13.16 | $55K | +1.7% | — |
| May 1SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 3,870143,842 held (−3%) | $13.06 | $51K | +2.5% | — |
| May 1SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 300143,542 held (−0%) | $13.84 | $4K | -3.3% | — |
| Apr 6SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 4,170147,712 held (−3%) | $13.43 | $56K | -0.4% | — |
| Mar 2SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 4,170151,882 held (−3%) | $15.01 | $63K | -10.9% | — |
| Mar 2SEC | Tim WatkinsCmo & Head Of Development | Sell Plan | 3,611 | $15.02 | $54K | -10.9% | — |
| Feb 26SEC | Carmine N. StengoneCEO, President | Sell Plan | 4,40014,954 held (−23%) | $16.02 | $70K | -16.5% | — |
| Feb 26SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 4,300156,052 held (−3%) | $16.03 | $69K | -16.5% | — |
| Feb 26SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 3,824156,052 held (−2%) | $16.01 | $61K | -16.4% | — |
| Feb 26SEC | Carmine N. StengoneCEO, President | Sell Plan | 2,70014,954 held (−15%) | $16.02 | $43K | -16.5% | — |
| Feb 20SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 100156,052 held (−0%) | $16.00 | $2K | -16.4% | — |
| Feb 13SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 400156,052 held (−0%) | $16.00 | $6K | -16.4% | — |
| Feb 13SEC | Carmine N. StengoneCEO, President | Sell Plan | 40014,954 held (−3%) | $16.00 | $6K | -16.4% | — |
| Feb 5SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 3,000157,222 held (−2%) | $14.82 | $44K | -9.7% | — |
| Feb 5SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 1,170156,052 held (−1%) | $15.25 | $18K | -12.3% | — |
| Jan 30SEC | Tim WatkinsCmo & Head Of Development | Sell Plan | 2,800811 held (−78%) | $14.09 | $39K | -5.0% | — |
| Jan 30SEC | Tim WatkinsCmo & Head Of Development | Sell Plan | 811 | $14.48 | $12K | -7.6% | — |
| Jan 6SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 3,670160,722 held (−2%) | $10.35 | $38K | +29.3% | — |
| Jan 6SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 500160,222 held (−0%) | $11.13 | $6K | +20.2% | — |
| Dec 30SEC | Daniel S. LorrainChief Scientific Officer | Sell Plan | 4,170164,392 held (−2%) | $12.23 | $51K | +9.4% | — |
| Dec 30SEC | Tim WatkinsCmo & Head Of Development | Sell Plan | 3,611 | $12.06 | $44K | +10.9% | — |
Insiders at Contineum Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Daniel S. LorrainChief Scientific Officer | — | $1.1M | Jul 10, 2026 | — |
| Carmine N. StengoneCEO, President | — | $401K | Sep 8, 2026 | — |
| Tim WatkinsCmo & Head Of Development | — | $323K | Jul 1, 2026 | — |
CTNM stock: common questions
Are Contineum Therapeutics, Inc. insiders buying CTNM stock?
In the past 12 months, 0 insiders reported open-market purchases of CTNM worth $0.
Are Contineum Therapeutics, Inc. insiders selling CTNM stock?
3 insiders reported sales worth $1.9M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is CTNM's 52-week range?
Over the past year CTNM has traded between $9.17 and $17.57. It last closed at $13.38 on Oct 9, 2026.